Latest Headlines

Latest Headlines

Roche wins FDA approval for a new lung cancer drug

Roche picked up an accelerated FDA approval for its latest lung cancer therapy, planning to market the treatment for severely ill patients while building the clinical case for wider use.

Roche lung cancer drug bags another 'breakthrough' at the FDA

Roche has won bragging rights to the FDA's new Breakthrough Therapy designation for its ALK inhibitor alectinib, a non-small cell lung cancer drug which will be featured at an upcoming presentation at the European Cancer Congress in Amsterdam at the end of this month.